Clene vs Lexaria Bioscience
CLNN and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLNN and LEXX compare
Lexaria Bioscience is the larger company, worth 2.2 times as much as Clene ($110M against $50.4M).
Clene grew revenue faster over the last twelve months (11.2% versus −68.5% for Lexaria Bioscience).
Lexaria Bioscience keeps more of each dollar of sales as profit, with a net margin of −3986% compared with −11271% at Clene.
Lexaria Bioscience scores higher on the StockData Score (8 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLNN | LEXX |
|---|---|---|
| Size and price | ||
| Market cap | $50.4M | $110M |
| Share price | $3.92 | $4.44 |
| Change, 1 year | −58.3% | −74.0% |
| Change, 5 years | −96.1% | −94.7% |
| Beta (5Y) | 0.79 | 0.82 |
| Employees | 79 | 134 |
| StockData Score | ||
| Total score | 1 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 212× (better) | 567× |
| P/B | – | 23.2× |
| FCF yield | – | −6.8% |
| Growth | ||
| Revenue growth (TTM) | 11.2% (better) | −68.5% |
| Revenue growth, 5Y average | −0.59% | 17.5% (better) |
| Profitability | ||
| Gross margin | 68.5% | 100% (better) |
| Operating margin | −8929% | −3973% (better) |
| Net margin | −11271% | −3986% (better) |
| FCF margin | – | −3849% |
| Return on equity | – | −150% |
| Return on invested capital | – | −602% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.3× | – |
| Current ratio | 0.85 | 10.60 (better) |
| Altman Z-score | −23.07 | 126.66 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −5.9% |
| Shareholder yield | 0.00% (better) | −5.9% |
| Ownership | ||
| Held by institutions | 24.8% | – |
| Held by insiders | 45.9% | 3.0% |
| Insider net buying, 12 months | −$5.6M | – |
| Short interest, % of float | 6.0% | 0.90% |
Go deeper
- CLNN stock overview
- CLNN income statement
- CLNN valuation and score
- LEXX stock overview
- LEXX income statement
- LEXX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.